• PharmEdaily
• Syntekabio

SyntekaBio Enters ‘Assetization Phase’ for AI Asset Program

• 송영두
• 2026.01.21
• 오전 09:27

NGeneBio Hits Upper Price Limit After Adopting LG AI Research Institute’s Solution[K-Bio Pulse]

• 신민준
• 2026.01.21
• 오전 08:10

Cellumed Hits Upper Limit on Hopes for Ownership Sale[K-Bio Pulse]

• 신민준
• 2026.01.20
• 오전 08:00

• Adbiotech
• CeluMed
• FromBio
• phamedaily

Unsolved Hair Loss Seeking a Breakthrough?...FromBio and Hyundai Pharm Surge [K-Bio Pulse]

• 유진희
• 2026.01.19
• 오전 08:00

BL Pharmtech Hits Upper Limit on Expectations for Molecular Glue Technology License Out[K-bio pul...

• 신민준
• 2026.01.16
• 오전 08:00

• U2Bio
• SamyangBiopharm
• AlphaAI
• phamedaily

Investment Sentiment Shifts to Mid Risk...High Return Bio Stocks: Samyang Biopharm and U2Bio Surg...

• 유진희
• 2026.01.15
• 오전 08:10

“Xellar Effect”… Woojung Bio Jumps[K-Bio Pulse]

• 김지완
• 2026.01.14
• 오전 09:56

AI Drug Discovery & Medical Sectors Take Flight[K-Bio Pulse]

• 김승권
• 2026.01.14
• 오전 08:00

Surge of the Medical Device Trio... Graphy·Livsmed·WSI Skyrocket [K-Bio Pulse]

• 김승권
• 2026.01.13
• 오전 08:00

Humedix Announces Syrian Approval for Three Types of HA Filler ‘Elravie Plus’

• 신민준
• 2026.01.12
• 오후 09:18